VIDEO: Expert discuses chorioretinal atrophy in patients treated with Luxturna

ByBart Leroy, MD, PhD

ByMichela Cimberle

Fact checked byEamon N. Dreisbach

ROME — In this Healio Video Perspective from the FLORetina-ICOOR meeting, Bart Leroy, MD, PhD, elucidates complications that may occur following gene therapy with Luxturna.

In most cases adverse reactions are limited to manageable inflammation, but some studies have shown that 15% to 25% of eyes treated with Luxturna (voretigene neparvovec-rzyl, Spark Therapeutics) have developed chorioretinal atrophy, Leroy explained.

“People have a tendency to lump [chorioretinal atrophy] together, but I prefer to divide it up into three types of chorioretinal atrophy that I see may have different causes,” he said.

Published by:

Sources/Disclosures

Collapse

Source:

Leroy B. RNA-based therapeutics for retinal diseases. Presented at: FLORetina-ICOOR; Nov. 30–Dec. 3, 2023; Rome.

Disclosures: Leroy reports receiving travel grant and research support from Novartis.

FLORetina-ICOOR meeting

Read more

VIDEO: Expert discuses chorioretinal atrophy in patients treated with Luxturna

Related Content